Mycobacterium malmoense was first described in 1977 by Schroder and Juhlin on the basis of 4 cases of pulmonary infection in the city of Malmo, Sweden, from which the organism gets its name. Most published case reports have originated in northern Europe and the United Kingdom; however, several reports, most from the United States, have [...]
Upon further examination at the Eastern Health Infectious Diseases clinic in December 2006, the patient’s vital signs were stable, she was afebrile, and there was no hemoptysis. The patient was cachetic with obvious tachypnea, but there were no signs of respiratory distress. On auscultation, the clinician noted decreased breath sounds and scattered crackles in the [...]
INTRODUCTION The incidence of nontuberculous mycobacteria (NTM) infections has increased over the past couple of decades, the most common clinical manifestation being pulmonary disease. Although Mycobacterium avium complex continues to be responsible for most cases, a number of other species may cause infection, including Mycobacterium malmoense, a slow-growing nonphotochromogenic mycobacterium that was first isolated in [...]
Speaker: Robert M. Califf, MD, Professor of Medicine, Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina. Baseline data from the Falsartan in cute Myocardial infarction Trial (VALIANT) demonstrated that the early use of beta blockade in patients with an acute myocardial infarction (AMI), complicated by heart failure and/or left ventricular [...]
Speaker: David E. Allie, MD, Director of Cardiothoracic and Vascular Surgery, Cardiovascular Institute of the South, Lafayette, Louisiana. Bivalirudin (Angiomax®, The Medicines Company), a novel direct thrombin inhibitor, has been shown to be safe and feasible as the sole anticoagulant in patients undergoing renal and iliac percutaneous peripheral interventions (PPIs) for peripheral vascular disease.
Speaker: Rosario A. Mercado-Young, MD, Fellow in Cardiology, University of Texas Health Science Center, San Antonio, Texas. An extended-release niacin formulation (Niaspan®, Kos) has been found to be safe, well tolerated, and effective in a wide range of patients with dyslipidemia, including those with diabetes.
Drug-Eluting Stents for Coronary Artery Lesions Speaker: Antonio Colombo, MD, Professor of Medicine, EMO Centre Cuone Columbus Hospital, Milan, Italy. A 12-month follow-up of the paclitaxel stent (Taxus™, Boston Scientific) study (TAXUS II) demonstrated that paclitaxel-elut-ing coronary stents were highly effective at one year after implantation with sustained benefits, as measured by decreased rates of [...]
© 2008 HIV/AIDS News & Information